logo
  

Bioverativ Inc. (BIVV) Vaulted To A New High After Bought By Sanofi

Bioverativ Inc. (BIVV) announced Monday morning that it has agreed to be acquired by Sanofi for $105 per share in cash, approximately $11.6 billion.

Bioverativ gapped open dramatically higher Monday, but moved in a narrow range throughout the session. The stock closed up by 39.68 at $103.79 on the highest volume of the year. Bioverativ soared to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT